Efficacy and Safety of Fixed-Dose Combination Therapy with Cilostazol and Rosuvastatin in Patients with Symptomatic Lower Extremity Peripheral Artery Disease: A Multicenter Randomized Controlled Trial.
Sep 2026· Cardiovascular Drugs and Therapy· 1 citation· 5 references
Medicine
TL;DR
In patients with symptomatic PAD, the addition of cilostazol to rosuvastatin significantly improved patient-reported health status and provided additional favorable effects on atherogenic lipid profiles beyond rosuvastatin therapy alone.
Abstract
Purpose
To evaluate whether combined cilostazol and rosuvastatin therapy improves health-related quality of life, walking performance, and lipid profiles compared with rosuvastatin alone in patients with symptomatic lower extremity peripheral artery disease (PAD).
Methods
This multicenter, double-blind, randomized placebo-controlled trial enrolled 260 patients with chronic lower extremity PAD (Rutherford category 2 or 3) at 52 sites in Korea. Participants were randomly assigned (1:1) to receive cilostazol 200 mg plus rosuvastatin or a matching placebo plus rosuvastatin for 24 weeks. The primary endpoint was the change in the Korean Peripheral Artery Questionnaire (KPAQ) summary score from baseline to week 24.
Results
A total of 257 patients were included in the full analysis set. The combination therapy group showed significantly greater improvement in the KPAQ summary score than in the rosuvastatin monotherapy group (least-squares mean change: 15.4 vs. 10.3 points; between-group difference 5.1 points, 95% confidence interval 1.5-8.7; P = 0.005). The treatment effect became statistically significant at week 12 and continued to increase through week 24. Treadmill walking distances improved in both groups; improvements were numerically greater with combination therapy but between-group differences were not significant at weeks 12 or 24. Compared with rosuvastatin monotherapy, combination therapy resulted in greater reductions in triglycerides and smaller increases in ApoB, together with greater increases in HDL cholesterol. Adverse events, adverse drug reactions, and discontinuations due to adverse events were numerically more frequent in the combination therapy group. Diarrhea was the only adverse event that occurred significantly more frequently, whereas no unexpected safety signals were observed.
Conclusion
In patients with symptomatic PAD, the addition of cilostazol to rosuvastatin significantly improved patient-reported health status and provided additional favorable effects on atherogenic lipid profiles beyond rosuvastatin therapy alone.
TRIAL REGISTRATION
ClinicalTrials.gov, NCT07600385.
INTRODUCTION
Stroke patients are at a higher risk of developing cognitive difficulties. Insulin resistance has been identified as a risk factor for decline in cognition, raising the possibility that pioglitazone, an insulin-sensitizing agent, might benefit stroke patients with cognitive impairment by improving insulin...
I. Osoro, Robert S. Wilson, M. Rajanandh· Current Vascular Pharmacolog...· 0 citations
BACKGROUND AND OBJECTIVES
Peripheral arterial disease (PAD) is associated with intermittent claudication (IC), leading to a lower quality of life. Although Ginkgo biloba extract (GbE) has been investigated for the treatment of IC, its clinical efficacy remains controversial. This study aimed to evaluate the efficacy an...
Onyou Kim, Seung-Hun Lee, J. Kim et al.· Korean Circulation Journal· 0 citations
Among patients with HR‑NICE within 24 h of onset, low‑dose ticagrelor plus aspirin significantly decreased the incidence of END within 7 days and improved neurological functional outcomes at 90 days compared with clopidogrel plus aspirin, without increasing the risk of bleeding.
Jia-Hui Liu, Hua Cao, Ming-Li Wang et al.· Journal of Neurology· 0 citations
Abstract Aims To evaluate whether dapagliflozin attenuates early cardiac functional and biomarker changes during anthracycline-based chemotherapy. Materials & Methods In this randomized, double-blind, placebo-controlled phase II trial, 94 adults were assigned 1:1 to dapagliflozin 10 mg once daily or placebo for 4 month...
H. Saeed, N. Mohammed Ali, R. Othman· Future Science OA· 0 citations
Administration of ilofotase alfa did not attenuate short- and longer-term renal function loss in patients at a high risk of renal functional impairment after on-pump cardiac surgery.
Louis Mourisse, M. Ostermann, Steven Thiessen et al.· Intensive Care Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.